Aurinia Pharmaceuticals Inc.AUPH
What Aurinia Pharmaceuticals Inc. does.
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (“LN”). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (“BAFF”) and a proliferation-inducing ligand (“APRIL”) for the potential treatment of autoimmune diseases.
Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the United States (“U.S.”), and Aurinia sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), for the European and Japanese market.
For the year ended December 31, 2025, cash flows from operating activities were $135.7 million, up 206% compared to $44.4 million in 2024.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $50.1M | $45.6M | $134.0M | $175.5M | $235.1M | $283.1M |
| Net income | -$102.7M | -$181.0M | -$108.2M | -$78.0M | $5.8M | $287.2M |
| Free cash flow | — | — | — | — | — | — |
More on AUPH.
- Aurinia Pharmaceuticals Inc. summary
- Aurinia Pharmaceuticals Inc. financial statements
- Aurinia Pharmaceuticals Inc. key metrics
- Aurinia Pharmaceuticals Inc. health scores and style box
- Aurinia Pharmaceuticals Inc. earnings
- Aurinia Pharmaceuticals Inc. dividends
- Aurinia Pharmaceuticals Inc. valuation
- Aurinia Pharmaceuticals Inc. ownership and insiders
- Aurinia Pharmaceuticals Inc. peers
Figures from Aurinia Pharmaceuticals Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.